(Q40001766)

16 September 2017

title

NSAIDs and colorectal cancer prevention (English)

1 reference

16 September 2017

1 reference

1 reference

Takeo Iwama

1

1 reference

16 September 2017

publication date

16 January 2009

1 reference

Journal of Gastroenterology

16 September 2017

published in

1 reference

16 September 2017

volume

44 Suppl 19

1 reference

16 September 2017

page(s)

72-76

1 reference

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

16 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-008-2265-7

The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-008-2265-7

Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention

21 January 2018

1 reference

12 December 2020

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

12 December 2020

Sulindac for polyposis of the colon.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.

1 reference

12 December 2020

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

12 December 2020

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

12 December 2020

Functional consequences of polyamine synthesis inhibition by L-alpha-difluoromethylornithine (DFMO): cellular mechanisms for DFMO-mediated ototoxicity

1 reference

12 December 2020

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

12 December 2020

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors

1 reference

12 December 2020

Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

1 reference

12 December 2020

Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors.

1 reference

12 December 2020

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

12 December 2020

Primary chemoprevention of familial adenomatous polyposis with sulindac

1 reference

12 December 2020

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

12 December 2020

Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants

1 reference

12 December 2020

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention

1 reference

12 December 2020

Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.

1 reference

12 December 2020

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

1 reference

12 December 2020

Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

10.1007/S00535-008-2265-7

Identifiers

DOI

1 reference

16 September 2017

1 reference